Monitoring Drug-Induced Lung Injury Expanding the Clinical Application of KL-6
1. Drug-Induced Lung Injury: A Diagnostic Challenge
Drug-induced lung injury may occur during treatment with anticancer agents, immune checkpoint inhibitors, targeted therapies, disease-modifying antirheumatic drugs, amiodarone and other implicated medicines. Symptoms and imaging patterns can overlap with infection, tumour progression, pulmonary oedema or worsening pre-existing interstitial lung disease (ILD).
Assessment therefore depends on the complete clinical picture: medication exposure and timing, symptoms, oxygenation, high-resolution computed tomography (HRCT), pulmonary function, microbiology and specialist review. KL-6 can add a non-invasive blood-based perspective on alveolar epithelial injury within this wider assessment.
Core message KL-6 is not a drug-specific marker. Its value is greatest when serial results are interpreted together with HRCT, symptoms, pulmonary function and infection-related testing.
2. What KL-6 Reflects
KL-6 is a high-molecular-weight MUC1 glycoprotein mainly expressed by type II alveolar epithelial cells. When epithelial injury, regeneration and alveolar-capillary leakage occur, KL-6 may enter the circulation. This makes it a useful supportive marker for ILD-related assessment and follow-up.
Why KL-6 Can Add Value in Drug-Related Lung Injury Assessment
1. Drug exposure / treatment
Targeted therapy, ICI, chemotherapy, antiarrhythmic, DMARD or other implicated drug
2. Alveolar epithelial injury
Type II pneumocyte injury, regeneration and increased alveolar-capillary permeability
3. KL-6 enters circulation
A blood-based signal reflecting epithelial injury burden—not a drug-specific marker
4. Integrated clinical interpretation
Use with symptoms, HRCT, PFT / DLCO, medication timeline and infection work-up
3. Where KL-6 Adds Clinical Value
|
Clinical focus |
Potential value |
How to interpret |
|
Triggered assessment |
Adds an epithelial-injury signal when new respiratory symptoms or HRCT changes raise concern for treatment-related ILD. |
Integrate with medication timing, oxygenation, HRCT and infection work-up.Elevated KL-6 can assist in the judgment of drug-induced lung injury, especially providing blood-based epithelial injury signals in the differential diagnosis of "abnormal HRCT but unknown etiology"
|
|
Dynamic monitoring |
Serial change may help show improvement, persistence or progression during follow-up. |
Trend direction is generally more informative than one isolated result. |
|
Differential support |
Can be combined with PCT, CRP and microbiology when infection and drug-related pneumonitis are both possible. |
No biomarker combination replaces imaging, cultures or multidisciplinary review. |
4. A Practical Monitoring Pathway
Suggested Monitoring Pathway (Adapt to Local Protocols)
1. Before therapy
Review prior ILD, thoracic radiation, lung function and drug-specific risk.
Consider a baseline KL-6 value when clinically appropriate.
2. During therapy
Track new cough, dyspnea, fever, oxygen saturation or exercise intolerance.
3. When lung injury is suspected
Prompt clinical review, HRCT, infection evaluation, PFT / DLCO when feasible, and KL-6 with complementary markers.
4. Follow-up
Use serial clinical, imaging and functional assessment. KL-6 trend may add context to improvement or progression.
5. KL-6 Testing on the Poclight C5000
|
Assay |
Sample |
Sample preparation |
Time |
Measuring range |
Reference cut-off |
Storage |
|
KL-6 |
Serum / Plasma |
50 µL into lysis solution; 50 µL mixture to reagent |
5 min |
50-5000 U/mL |
≤400 U/mL |
2-30°C / 18 months |
Our standout features:
1. Small Sample Volume & Rapid Results
Small sample volume of serum or plasma needed, with 5-15 minute turnaround, ideal for fast clinical decisions.
2. Freeze-dried reagents: no cold chain, 18 months shelf life, simplifying storage and transport.
3. High accuracy and excellent precision (CV < 5%)
4. Applicable with the C5000 POC CLIA Analyzer: 3-Step Operation, Maintenance-Free